Year None 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 October 26, 2026 Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease Go to October 22, 2026 Medicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference Go to October 5, 2026 Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026 Go to October 1, 2026 Medicenna Announces Results of Annual General and Special Meeting of Shareholders Go to September 24, 2026 Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting Go to September 3, 2026 Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference Go to Pagination Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last »
October 26, 2026 Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease Go to
October 22, 2026 Medicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference Go to
October 5, 2026 Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026 Go to
October 1, 2026 Medicenna Announces Results of Annual General and Special Meeting of Shareholders Go to
September 24, 2026 Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting Go to
September 3, 2026 Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference Go to
